Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Monopar Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Monopar Therapeutics's regulatory disclosures and financial reporting.
Monopar Therapeutics Inc. is asking stockholders at its June 22, 2026 annual meeting to elect six directors, including new nominee Nicole Sweeny, approve executive pay on an advisory basis, adopt a new 2026 Stock Incentive Plan, and ratify BPM LLP as auditor.
Stockholders of record as of April 27, 2026, when 6,698,778 common shares were outstanding, may vote. The 2026 plan would add 600,000 new shares plus remaining and recycled shares from the prior plan, with new award capacity equal to 9.2% of fully diluted common stock as of March 31, 2026. The proxy also details director fees, substantial 2025 equity and cash compensation for executives, change-in-control severance protections, and pay-versus-performance disclosures comparing compensation actually paid to total shareholder return and net losses.
Monopar Therapeutics Inc. is highlighting new Phase 3 data for ALXN1840 (tiomolibdate choline) in Wilson disease. Analyses from the randomized controlled FoCus trial showed greater neurologic improvement and significantly less worsening versus standard of care through Week 48 in patients with neurologic symptoms at baseline, with durable benefit over multiple years of treatment. These results, presented at the American Academy of Neurology 2026 meeting in a late-breaker oral and poster session, support Monopar’s plan to advance ALXN1840 toward a New Drug Application submission to the U.S. Food and Drug Administration in mid-2026.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported routine equity compensation activity. On March 31, 2026, 6,732 restricted stock units vested and were settled into an equal number of common shares at an exercise price of $0.00 per share.
Of these shares, 1,972 were withheld by the issuer at $54.79 per share to cover applicable tax withholding obligations. Following these transactions, Robinson held 90,478 shares of common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine increased his direct equity stake through RSU vesting. On March 31, 2026, 3,514 restricted stock units vested and were settled into an equal number of common shares at a conversion price of $0.00 per share.
To cover withholding taxes on this vesting, 1,571 common shares were withheld by the company at a value of $54.79 per share, rather than sold in the open market. After these transactions, Cittadine directly owned 52,669 shares of Monopar Therapeutics common stock.
Monopar Therapeutics filed Amendment No. 1 to its 2025 annual report to correct the date on the independent auditor’s report from March 27, 2025 to March 27, 2026 and update related officer certifications. The amendment re-presents full 2025 financials, which show a net loss of $13.7 million and year-end cash, cash equivalents and investments totaling about $140.7 million against stockholders’ equity of $137.8 million. Management notes an accumulated deficit of $89.5 million and expects existing cash resources to fund operations at least through December 31, 2027.
Monopar Therapeutics reported fourth-quarter and full-year 2025 results and provided an update on its drug programs. Cash, cash equivalents and short-term investments were $140.4 million as of December 31, 2025, and the company expects this to fund operations through at least December 31, 2027.
Net loss was $5.2 million, or $0.61 per share, for Q4 2025 and $13.7 million, or $1.85 per share, for full-year 2025, both lower than in 2024. R&D expenses fell mainly because 2024 included one-time ALXN1840 in-licensing costs, while G&A expenses rose due to higher personnel and patent expenses.
Monopar plans to submit a New Drug Application for ALXN1840 for Wilson disease in mid-2026 and is advancing its MNPR-101 radiopharmaceutical programs. The leadership team was expanded with a new Chief Commercial and Strategy Officer to support a potential ALXN1840 launch.
Monopar Therapeutics Inc. is a clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceuticals for advanced cancers. ALXN1840, in-licensed from Alexion in 2024, has Phase 3 data and U.S./EU orphan and FDA Fast Track designations, but regulators may still require more studies before any approval.
The company is running Phase 1 imaging and therapeutic trials in Australia for MNPR-101-Zr and MNPR-101-Lu, plus an FDA-authorized expanded access program in the U.S., and is advancing MNPR-101-Ac preclinically. Cash, cash equivalents and investments were $140.4 million as of December 31, 2025, which management expects to fund operations at least through December 31, 2027, including an anticipated mid-2026 NDA submission for ALXN1840. The 10-K highlights significant future funding needs to commercialize ALXN1840, complete radiopharmaceutical trials, meet up to $94.0 million in Alexion milestones plus 10–20% tiered royalties, and manage intense competition, manufacturing, logistics, and regulatory risks.
Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.
Monopar Therapeutics granted Chief Clinical Science Officer Susan Rodriguez stock options covering 48,728 shares on March 2, 2026. The options were reported at a price of $0.0000 per share and are held directly.
According to the vesting terms, 6/48ths of the options vest on September 2, 2026, with the remaining 1/48th vesting each month thereafter. After this grant, Rodriguez was reported as holding 48,728 stock options in total.
Monopar Therapeutics officer Susan Rodriguez filed an initial statement of beneficial ownership on Form 3. She is listed as the company’s CCSO, and the filing does not report any insider stock transactions, focusing instead on establishing her status as a reporting officer.
Monopar Therapeutics filed an 8-K to share that it has appointed seasoned biopharma executive Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. She will lead commercial strategy and infrastructure as the company prepares a planned NDA submission in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease.
Rodriguez brings over 30 years of leadership experience, including senior roles at Avadel Pharmaceuticals, Ardelyx, Tolmar Pharmaceuticals, and Abbott. Her background spans launching rare disease therapies, building commercial organizations, and contributing to Avadel’s acquisition by Alkermes for over $2 billion. The filing also highlights Monopar’s broader pipeline of radiopharmaceutical programs targeting advanced cancers.